A Phase 3 randomized, open-label trial of selinexor, pomalidomide, and dexamethasone versus elotuzumab, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma

被引：0
|
作者：
Weisel, Katja [1 ]
Bentur, Ohad [2 ]
Van Domelen, Dane [2 ]
Boccadoro, Mario [3 ]
Sonneveld, Pieter [4 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[2] Karyopharm, Newton, MA USA
[3] Cattedra Ematol, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy
[4] Erasmus MC Canc Inst, Rotterdam, Netherlands
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-323
引用
收藏
页码：S216 / S217
页数：2
相关论文
共 50 条
  • [31] Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
    Richardson, Paul G.
    Perrot, Aurore
    San Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Mace, Sandrine
    Zhang, Rick
    Dubin, Franck
    Morisse, Mony Chenda
    Anderson, Kenneth C.
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 2239 - 2249
  • [32] Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
    Richardson, Paul G.
    Perrot, Aurore
    San Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Mace, Sandrine
    Zhang, Rick
    Dubin, Franck
    Morisse, Mony Chenda
    Anderson, Kenneth C.
    HAEMATOLOGICA, 2024, 109 (07) : 2239 - 2249
  • [33] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
    Attal, Michel
    Richardson, Paul G.
    Rajkumar, S. Vincent
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Mace, Sandrine
    Corzo, Kathryn P.
    Campana, Frank
    Le-Guennec, Solenn
    Dubin, Franck
    Anderson, Kenneth C.
    LANCET, 2019, 394 (10214): : 2096 - 2107
  • [34] Phase 3 Study of Pomalidomide with Cyclophosphamide and Dexamethasone Versus Pomalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)
    Chng, Wee-Joo
    Li, Xinhua
    Lin, Cindy
    Kim, Jin Seok
    Handa, Hiroshi
    Durie, Brian G. M.
    BLOOD, 2020, 136
  • [35] A PHASE III RANDOMIZED, OPEN-LABEL STUDY OF ISATUXIMAB (SAR650984) PLUS POMALIDOMIDE AND DEXAMETHASONE VERSUS POM AND DEX IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Richardson, P.
    Attal, M.
    San Miguel, J.
    Campana, F.
    Le-Guennec, S.
    Hui, A. -M.
    Risse, M. -L.
    Anderson, K.
    HAEMATOLOGICA, 2017, 102 : 779 - 779
  • [36] Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma
    Chen, Christine
    Kotb, Rami
    Sebag, Michael
    LeBlanc, Richard
    Sutherland, Heather J.
    White, Darrell
    Venner, Christopher P.
    Kouroukis, Tom
    Bergstrom, Debra
    McCurdy, Arleigh
    Lalancette, Marc
    Bensinger, William
    Lentzsch, Suzanne
    Del Col, Aldo
    Kauffman, Michael
    Shacham, Sharon
    Jeha, Jacqueline
    Picklesimer, Carla
    Saint-Martin, Jean-Richard
    Choe-Juliak, Cassandra
    Bahlis, Nizar J.
    BLOOD, 2016, 128 (22)
  • [37] A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed/Refractory Multiple Myeloma Patients
    Berenson, James
    Martinez, Daisy
    Spektor, Tanya
    Sanchez, Armando
    Ghermezi, Matthew
    Swift, Regina
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Lim, Stephen
    Vescio, Robert
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E249 - E250
  • [38] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
    San Miguel, Jesus
    Weisel, Katja
    Moreau, Philippe
    Lacy, Martha
    Song, Kevin
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Banos, Anne
    Oriol, Albert
    Alegre, Adrian
    Chen, Christine
    Cavo, Michele
    Garderet, Laurent
    Ivanova, Valentina
    Martinez-Lopez, Joaquin
    Belch, Andrew
    Palumbo, Antonio
    Schey, Stephen
    Sonneveld, Pieter
    Yu, Xin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed
    Dimopoulos, Meletios
    LANCET ONCOLOGY, 2013, 14 (11): : 1055 - 1066
  • [39] KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma
    Mateos, M. V.
    Blacklock, H.
    Rocafiguera, A. O.
    Iida, S.
    Jagannath, S.
    Lonial, S.
    Kher, U.
    Farooqui, M.
    Marinello, P.
    San-Miguel, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [40] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
    Shah, Jatin J.
    Stadtmauer, Edward A.
    Abonour, Rafat
    Cohen, Adam D.
    Bensinger, William I.
    Gasparetto, Cristina
    Kaufman, Jonathan L.
    Lentzsch, Suzanne
    Vogl, Dan T.
    Gomes, Christina L.
    Pascucci, Natalia
    Smith, David D.
    Orlowski, Robert Z.
    Durie, Brian G. M.
    BLOOD, 2015, 126 (20) : 2284 - 2290
12345